Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA179197
Max Phase: Preclinical
Molecular Formula: C19H16O5
Molecular Weight: 324.33
Molecule Type: Small molecule
Associated Items:
ID: ALA179197
Max Phase: Preclinical
Molecular Formula: C19H16O5
Molecular Weight: 324.33
Molecule Type: Small molecule
Associated Items:
Synonyms (1): SCH-68631
Synonyms from Alternative Forms(1):
Canonical SMILES: CCCC(=O)c1cc2c(c(O)c1C)C(=O)C(=O)c1c(O)cccc1-2
Standard InChI: InChI=1S/C19H16O5/c1-3-5-13(20)11-8-12-10-6-4-7-14(21)15(10)18(23)19(24)16(12)17(22)9(11)2/h4,6-8,21-22H,3,5H2,1-2H3
Standard InChI Key: YJQYHFMKGAVKDP-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 324.33 | Molecular Weight (Monoisotopic): 324.0998 | AlogP: 3.44 | #Rotatable Bonds: 3 |
Polar Surface Area: 91.67 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 7.69 | CX Basic pKa: | CX LogP: 4.83 | CX LogD: 4.63 |
Aromatic Rings: 2 | Heavy Atoms: 24 | QED Weighted: 0.67 | Np Likeness Score: 1.01 |
1. Gordon CP, Keller PA.. (2005) Control of hepatitis C: a medicinal chemistry perspective., 48 (1): [PMID:15633995] [10.1021/jm0400101] |
2. Dai J, Carté BK, Sidebottom PJ, Sek Yew AL, Ng S, Huang Y, Butler MS.. (2001) Circumdatin G, a new alkaloid from the fungus Aspergillus ochraceus., 64 (1): [PMID:11170686] [10.1021/np000381u] |
3. Hahne G, Grossmann TN.. (2013) Direct targeting of β-catenin: Inhibition of protein-protein interactions for the inactivation of Wnt signaling., 21 (14): [PMID:23566764] [10.1016/j.bmc.2013.02.050] |
4. Radwan AA, Al-Mohanna F, Alanazi FK, Manogaran PS, Al-Dhfyan A.. (2016) Target β-catenin/CD44/Nanog axis in colon cancer cells by certain N'-(2-oxoindolin-3-ylidene)-2-(benzyloxy)benzohydrazides., 26 (7): [PMID:26944615] [10.1016/j.bmcl.2016.02.064] |
5. Phull MS, Jadav SS, Gundla R, Mainkar PS.. (2021) A perspective on medicinal chemistry approaches towards adenomatous polyposis coli and Wnt signal based colorectal cancer inhibitors., 212 [PMID:33445154] [10.1016/j.ejmech.2020.113149] |
Source(1):